Determination of a Measure of a Glycation End-Product or Disease State Using Tissue Fluorescence of Various Sites

Abstract

Embodiments of the present invention provide an apparatus suitable for determining properties of in vivo tissue. An illumination system communicates light at a plurality of broadband ranges to an optical probe, which can comprise a flexible probe. Light homogenizers and mode scramblers can be employed in some embodiments. The optical probe can physically contact the tissue, or can be maintained separate from the tissue. The optical probe receives light from the illumination system and transmits it to tissue, and receives light diffusely reflected in response to the broadband light, emitted from the in vivo tissue by fluorescence thereof in response to the broadband light, or a combination thereof. The optical probe can communicate the light to a spectrograph which produces a signal representative of the spectral properties of the light. An analysis system determines a property of the in vivo tissue from the spectral properties.

Description

CROSS REFERENCES TO RELATED APPLICATIONS[0001]This application claims priority as a continuation of U.S. application Ser. No. 11 / 675,524, filed Feb. 15, 2007; and to the applications which said Ser. No. 11 / 675,524 claims priority. Said Ser. No. 11 / 675,524 application (1) claims priority to U.S. provisional application 60 / 781,638, filed Mar. 10, 2006; and (2) claims priority as a continuation in part of U.S. application Ser. No. 11 / 350,916, filed Feb. 9, 2006, which application claimed priority to U.S. provisional application 60 / 651,679, filed Feb. 9, 2005; and (3) claims priority as a continuation in part of U.S. application Ser. No. 11 / 624,214, filed Jan. 17, 2007, which application claims priority as a continuation-in-part of U.S. application Ser. No. 11 / 561,380, filed Nov. 17, 2006, which was a continuation of U.S. application Ser. No. 10 / 972,173, filed Oct. 22, 2004, which was a continuation in part of U.S. application Ser. No. 10 / 116,272, filed Apr. 4, 2002, and claimed the ben...

AI Technical Summary

Benefits of technology

The method significantly improves the sensitivity of diabetes detection, identifying approximately 29% more individuals with undiagnosed abnormal glucose tolerance compared to traditional methods, while being more convenient and providing rapid results, facilitating early intervention and prevention of diabetes-related complications.

Problems solved by technology

However, current screening methods for type 2 diabetes and pre-diabetes are inadequate due to their inconvenience and inaccuracy.

FPG also suffers from poor sensitivity (40-60%) contributing to late diagnoses.

Images